Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register

About Us
Pharmalicensing - Open Innovation for the life sciences
 
Our Products
Overview
Partnering Search
Company Profiling
PL Intelligence
Reports
Partnering Consulting
Due Diligence
Comparison
 
PL Intelligence
Overview
Industry news
Deals review
Press releases
Articles
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Due Diligence
Overview
Top Applications
Online Panel Discussions
Request Consultation
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire
Jobs
Forums
 
Contact Pharmalicensing
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing
is a division of
UTEK Corporation
Industry news

News of the day

CombiMatrix Publishes Clinical Study of Its HerScan(tm) Breast Cancer Test

MUKILTEO, Wash., Jun 3, 2009 -- CombiMatrix Corporation (Nasdaq:CBMX) today announced that the validation study performed by its wholly owned subsidiary, Combimatrix Molecular Diagnostics (CMDX), in collaboration with the Department of Pathology at the University of Texas Health Science Center in San Antonio, TX (UTHSCSA) is available as an advance online publication in the official journal of the United States and Canadian Academy of Pathology (USCAP), Modern Pathology. more

Novasep acquires bioprocess development specialist and contract manufacturer Henogen

Pompey, France, July 2, 2009 - Novasep, a leading producer of active pharmaceutical ingredients (APIs) and purification technologies for the life science industries, announces today the acquisition of Henogen, a contract manufacturing organization (CMO) offering bioprocess development and manufacturing services from the cell bank to the supply of clinical products. The move adds a complementary, market-leading range of upstream processing capabilities and services to Novasep's comprehensive... more

Open Briefing

July 02, 2009-- Bionomics Limited (ASX: BNO) today announced it had identified a safe dosage for Phase II clinical trials of BNC105, its novel vascular disrupting agent (VDA) for the treatment of solid tumour types, and that it has contracted Hoosier Oncology Group Inc. ("HOG") to conduct a Phase II trial to evaluate the efficacy of BNC105 in renal cell carcinoma. Bionomics also recently initiated a Phase I clinical trial for BNC210, its potential blockbuster antianxiety drug. To what extent... more

Industry news search

Search the Pharmalicensing Industry news by keyword. Alternatively our advanced search allows you to query by category and therapeutic target.
 
Category Therapeutic target
 
To choose more then one item on the list hold CTRL button while selecting. To deselect items press CTRL button and deselect.

Latest news by therapeutic target

Latest news by category

Clients in focus...

Get the Flash Player to see this rotator.

Partnering consultation free of charge
The countdown has started...
Americas Antibody Congress
Press releases: Pharmalicensing current industry press releases.

© Copyright 1995-2009 Pharmalicensing, is a division of UTEK Corporation All rights reserved. Terms and Conditions | Site map | Contact us